Loading
companiesCompany
3D Medicines
3D Medicines is a Chinese biotechnology company that co-developed envafolimab, the first subcutaneous PD-L1 antibody, approved in China in 2021 for microsatellite instability-high solid tumours.
Also called: 3D Medicines (Sichuan) Co., Ltd.3D Medicines Inc.思路迪
Overview
3D Medicines, headquartered in Sichuan with research in Shanghai and listed in Hong Kong since 2022, develops immuno-oncology antibodies. With Alphamab Oncology and Tracon it brought envafolimab (KN035), a single-domain PD-L1 antibody given by subcutaneous injection, to approval in China in November 2021 for previously treated MSI-high or dMMR advanced solid tumours, and it runs phase 3 trials of the drug in combination with chemotherapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Chengdu, CN
Scorecard
All companies#193of 1244 companies, score 30
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +19
1 approved, 0 in phase 3, 0 earlier, 1 targets, 88 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedSingle-domain antibody (anti-PD-L1, subcutaneous)
Envafolimab · Enweida
Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency.
fronts
targets
drugs
ApprovedSingle-domain antibody (anti-PD-L1, subcutaneous)
Envafolimab · Enweida
companies
trials
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid TumorsKN035 for dMMR/MSI-H Advanced Solid TumorsMulticenter Phase 2 Study of Envafolimab in Biliary Tract CancersPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsPhase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLCProgrammed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCStudy of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer